Alexion Trades Lower Amid Amgen-Celgene News

Loading...
Loading...

Alexion Pharmaceuticals, Inc. ALXN shares climbed 7.5% last Thursday on rumors of a potential buyout and have since given up all of those gains.

Alexion develops therapies for rare diseases and has been rumored to be a takeover target for Amgen, Inc. AMGN for about a year. The speculation gained further momentum last week when Spanish publication Intereconomia carried a report Amgen is close to buying Alexion for $200 per share, suggesting a roughly 74% premium.

Subsequently on Thursday, Mizuho Securities said the report could have some merit to it.

The stock fell 6.6% Friday and is down about 2.5% Monday after Amgen announced a deal to buy Celgene Corporation CELG's psoriasis drug Otezla for $13.4 billion, as part of a regulatory requirement to consummate its merger with Bristol-Myers Squibb Co BMY.

The weakness seen Monday is apparently stemming from pessimism concerning Amgen making a shy at Alexion in the wake of the multi-billion dollars it is coughing up for Otezla.

At time of publication, Alexion shares were down 2.54% to $112.30 on below-average volume.

Related Links:

Good News For Bad Cholesterol Drug Sends Medicines Company Shares Flying

The Week Ahead In Biotech: A Quiet One Ahead Of Labor Day Weekend

Loading...
Loading...
Posted In: BiotechMoversTrading IdeasGeneralOTEZLA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...